NEW YORK (GenomeWeb) – DiaCarta and MIODx today said they plan to codevelop a diagnostic test to predict immunotherapy response based on MIODx's immune sequencing technology, ClonoMap.

The test will be developed and validated at DiaCarta's CLIA-certified laboratories in the San Francisco Bay Area and Nanjing, China. MIODx is an early-stage immunogenomics company based in San Jose, California, developing a T-cell receptor and B-cell receptor sequencing platform.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.